The road to Unicorn status by BICO founder Erik Gatenholm
..............................................................
GU Ventures shares news and information about its business, people, projects, companies, alumni and partners.
..............................................................
Erik Gatenholm, founder and former CEO of BICO, is a visionary Unicorn builder in the biotechnology and life science industry. He has just handed over the wheels to a new CEO at BICO. GU Ventures presents a short film where he shares the start of his journey to inspire and to tell the new entrepreneurs about the start of the collaboration with the GU Ventures incubator, when the development of the successful company began.
”I am forever grateful for the last 7 years together with all our colleagues, shareholders, and customers. I am excited to have Maria Forss take over the reins and take the company to the next level”, says Erik Gatenholm.
"Erik and his co-founders have been a total pleasure to work with during the years. He himself is one of the strongest and most dedicated entrepreneurs that I have ever experienced and I am truly impressed of the fantastic results that he and his team have achieved globally so far." says Klementina Österberg, CEO, GU Ventures.
GU Ventures continues to support and showcase groundbreaking companies like BICO, that play a crucial role in shaping the landscape of the future of life science.
ABOUT BICO
BICO creates the future of life-saving treatments by aiming to reduce the organ shortage and speed up drug development by providing accessible life science solutions that combine biology and technology.
BICO is a leading provider of life science solutions and laboratory automation that enable more efficient development of new treatments with more specificity and less need for animal testing.
The company uses bioconvergence as its operating system, combining advanced technologies with biology to streamline and automate workflows within the pharmaceutical and biopharma industries.
With 32,000+ instruments installed in over 65 countries, BICO products and solutions are found in more than 3,500 laboratories, including the world’s top 20 pharmaceutical companies, and have been cited in over 11,000 publications.
Operating through three business areas – Bioprinting, Biosciences and Bioautomation – the BICO Group strives towards the long-term ambition of enabling the reduction of the world’s organ shortage and speeding up drug development to create the future of life-saving treatments.
BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. www.bico.com
Their latest Pressreleases are:
BICO company Biosero has signed an agreement to develop laboratory automation solutions to a value of 28 MUSD: https://bico.com/single-press-...
BICO has completed the divestment of the Berlin property for a total of EUR 21m: https://bico.com/single-press-...
Publication of BICO Group interim report July – September 2023: https://bico.com/single-press-...
Maria Forss assumes office as BICO’s CEO and President on November 20, 2023: https://bico.com/single-press-...